

PERSPECTIVES ON SCHISTOSOMIASIS ELIMINATION NOVEMBER 10-13TH 2024 | SALVADOR - BAHIA

XVII INTERNATIONAL SYMPOSIUM ON

Indicate the format in which you wish to present your work: Dester

er 🛛 🔀 Oral Presentation

TITLE

DEVELOPMENT OF A CRISPR-BASED DIAGNOSTIC TOOL FOR SCHISTOSOMIASIS

AUTHORS

You, H.*1; MacGregor, S.R.1; Cai, P.1; Gordon, C.A.1; Graeff-Teixeira, C.2; Egwang, T.G.3; Jones, M.K.1, 4

AFFILIATIONS

¹ Immunology Department, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia ² Department of Pathology, Infectious Diseases Unit, Health Sciences Center, Universidade Federal do Espírito

- Santo, Vitória, Brazil
- ³ Department of Immunology and Parasitology, Med Biotech Laboratories, Kampala, Uganda
- ⁴ School of Veterinary Science, The University of Queensland, Brisbane, Queensland, Australia

ABSTRACT

Objectives: Effective diagnostics are needed urgently for rapid mapping of schistosomiasis transmission sites and in monitoring control programs, but many current diagnostic procedures lack the requisite sensitivity, portability and cost-effectiveness needed for use in resource-poor settings. Our study aims to develop an ultra-sensitive, field-friendly, potable and affordable point-of-care CRISPR-based diagnostic tool for detecting schistosomiasis in endemic countries.

Methodology: For the first time, we developed a CRISPR-based diagnostic platform SHERLOCK (Specific High-Sensitivity Enzymatic Reporter UnLOCKing) for schistosomiasis diagnosis, by combining recombinase polymerase amplification (RPA), which can be performed at a single temperature at 37[•], with CRISPR-Cas13 detection, the results can be visualized either through fluorescent or colorimetric readout on a lateral flow strip. We present the novel SHERLOCK-based diagnostic assays for the detection of Schistosoma japonicum and S. mansoni infection. The assays were validated using faecal samples obtained from a mouse model infected with S. japonicum or S. mansoni, as well as clinical faecal and serum samples obtained from an S. japonicum-endemic area in Northern Samar, the Philippines and an S. mansoni-endemic area in Mayuge, Uganda. We further simplified the SHERLOCK system by combining the two-step process into a one-pot reaction, making it more user-friendly for field applications. We then compared the sensitivity of the one-pot reaction to the original two-step SHERLOCK process.

Results: The results we will present show that the CRISPR-based system is specific, sensitive, cost-effective and user-friendly. Although the assay does not require the specialized equipment or expertise necessary for real-time PCR detection, it provides a similar level of sensitivity. We found sensitivity of one-pot SHERLCOK was slightly, but not significantly, reduced compared to two-step reaction.

Conclusion: This novel schistosomiasis diagnostic test provides the basis for the development of accurate and field-friendly CRISPR-based diagnostics for other parasitic neglected tropical diseases, both as powerful point-of-care tests and as surveillance tools.

KEYWORDS

CRISPR-Based Diagnosis; SHERLOCK, Schistosomiasis, Point-of-Care, Helminth Coinfection

FINANCIAL SUPPORT

National Health and Medical Research Council (NHMRC) of Australia; Australian Infectious Diseases Research Centre seed grant